Keryx Biopharmaceuticals, Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 12 Calls Today's Calls

Call Details Keryx Biopharmaceuticals, Inc. Earnings Conference Call (Q1 2008) Mon, May 12, 2008, 8:30 am Eastern Listen to the archived event audio About Keryx Biopharmaceuticals, Inc. (NasdaqCM:KERX) Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. Its endocrine/renal products include Sulonex, a Phase III and Phase IV clinical stage product for the treatment of diabetic nephropathy; and Zerenex, a Phase II clinical stage product for the treatment of hyperphosphatemia in patients with end-stage renal disease. The company’s oncology products include KRX-0401, a Phase II clinical stage product for the treatment of renal cancer and other multiple forms of cancer; KRX-0402, a Phase II clinical stage product for the treatment of brain cancer; KRX-0601, a Phase II clinical stage product for the treatment of multiple forms of cancer; and KRX-0404, a pre-clinical stage product for the treatment of multiple forms of cancer. It also develops neurology products, including KRX-0701, a Phase II clinical stage product for the treatment of diabetic neuropathy; and KRX-0501, a Phase I clinical stage product for the treatment of neurological disorders. Keryx Biopharmaceuticals, Inc. has strategic alliances with Alfa Wassermann S.p.A.; Collaborative Study Group; Opocrin, S.p.A.; AEterna Zentaris, Inc.; The National Institutes of Health; Panion & BF Biotech, Inc.; Kyowa Hakko Kogyo Co., Ltd.; AusAm Biotechnologies, Inc.; Degussa AG; Japan Tobacco, Inc.; and Torii Pharmaceutical Co., Ltd. for the manufacture and commercialization of its products. The company was founded in 1998. It was formerly known as Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999. Further, the company changed its name to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals, Inc. is based in New York, New York. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings